Skip to main content
Log in

‘Ampligen’

seeing benefits in chronic fatigue syndrome

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

For 30 years, double-stranded RNA has been used in veterinary applications but has been considered too toxic for human use. However, recent molecular manipulation techniques have improved its tolerability, resulting in the agent ‘Ampligen’ [HemispheRx], which has been approved by the US FDA for clinical trials. The potential of ‘Ampligen’ for treating patients with chronic fatigue syndrome (CFS) was discussed at an international meeting entitled ‘The Clinical and Scientific Basis of Chronic Fatigue Syndrome: From Myth Towards Management’ [ Sydney, Australia; February 1998 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrigan, P. ‘Ampligen’. Inpharma Wkly. 1128, 9–10 (1998). https://doi.org/10.2165/00128413-199811280-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199811280-00015

Keywords

Navigation